Shilpa Gupta shared on X:
“WorldGU24, An amazing session with The Uromigos, Tom Powles, Brian Rini with community oncologists to discuss the real world practice patterns in GU cancers.”
Michael Harrison, Clinical Researcher at Duke Cancer Institute, commented on Shilpa Gupta’s post:
“I appreciate Uromigos getting down to brass tacks as to how trial data affects day to day clinical GU practice!
Great insights from community oncology colleagues.”
Source: Shilpa Gupta/X and Michael Harrison/X
Shilpa Gupta is the Director of Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic. Dr. Gupta’s extensive research focuses on novel drug development and biomarkers of response/resistance in bladder cancer, contributing to numerous published works and leadership roles in clinical trials. Shilpa also got promoted to Professor of Medicine at Cleveland Clinic.